Form 8-K - Current report:
SEC Accession No. 0001829126-24-005656
Filing Date
2024-08-19
Accepted
2024-08-19 16:22:56
Documents
16
Period of Report
2024-08-19
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K titanpharma_8k.htm   iXBRL 8-K 80608
2 EXHIBIT 2.1 titanpharma_ex2-1.htm EX-2.1 802525
3 EXHIBIT 99.1 titanpharma_ex99-1.htm EX-99.1 21279
4 GRAPHIC ex99-1_001.jpg GRAPHIC 11053
  Complete submission text file 0001829126-24-005656.txt   1270017

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE ttnp-20240819.xsd EX-101.SCH 2991
6 XBRL LABEL FILE ttnp-20240819_lab.xml EX-101.LAB 34240
7 XBRL PRESENTATION FILE ttnp-20240819_pre.xml EX-101.PRE 22343
18 EXTRACTED XBRL INSTANCE DOCUMENT titanpharma_8k_htm.xml XML 3686
Mailing Address 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA 94080
Business Address 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA 94080 6502444990
TITAN PHARMACEUTICALS INC (Filer) CIK: 0000910267 (see all company filings)

EIN.: 943171940 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-13341 | Film No.: 241220860
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)